First things first, be sure to sign up for the first ever Millionaire Maker Summit! Kyle Dennis will be holding the event on Thursday at 4:30 PM Eastern!
[Ed. Note: Kyle Dennis runs BiotechBreakouts.com. He is an event-based trader, who prefers low-priced and small-cap biotech stocks. He has no stocks, options or open orders in MRNS, but day-traded it on Sept. 9 for a smallgain. He has no shares, options or open orders on SAGE. To learn more JOIN THIS SPECIAL ONLINE EVENT: 3-Step Plan Kyle Used to Turn $15,253 into $2,855,475 and download his FREE “The $2.9 Million Biotech Trader Playbook here!]
I took some nice profits today on a few names. I sold half of my CLSD and OTIC, along with all my HTBX. All three were in the green and booked about $5000 in overall gains!
I also sold my starter position in CRMD. The company said that they expect their interim data out in the second quarter, instead of March. That delay is causing a dip, but I expect it to settle out and head back higher in a few weeks. I’ll likely pick up shares after their earnings call sometime in March. Until then it’ll just be on the watch list.
I still am holding onto ANTH, CLSD, and OTIC overall though. I decided to lighten up as the catalysts get closer and the markets are likely hitting a short term resistance point soon.
Be sure to study up on the names below!
Just a reminder, charts and targets are updated every Monday morning!
Catalyst Swing names (1 – 4 week holds) I am watching…
Rigel Pharmaceuticals (RIGL)
Catalyst Dates: FDA approval date of April 17th for immune thrombocytopenic purpura
Buy Zone: $3.50 to $3.90
Profit Zone: $4.50 or higher
Stop Zone: $3.40 or below
Clovis Oncology (CLVS)
Catalyst Dates: FDA approval date of April 6th for ovarian cancer
Buy Zone: $51.00 to $54.00
Profit Zone: $60.00 or higher
Stop Zone: $49.00 or below
Savara (SVRA)
Catalyst Dates: Phase 2 heart failure data due on March 11th
Buy Zone: $11.75 to $12.50
Profit Zone: $14.00 or higher
Stop Zone: $11.00 or below
Ultragenyx Pharmaceuticals (RARE)
Catalyst Dates: FDA approval date of April 17th for X-linked Hypophosphatemia
Buy Zone: $44.00 to $46.00
Profit Zone: $55.00 or higher
Stop Zone: $41.00 or below
Anthera Pharmaceuticals (ANTH)
Catalyst Dates: Phase 3 analysis due in March
Buy Zone: $1.40 to $1.55
Profit Zone: $1.85 or higher
Stop Zone: $1.25 or below
Progenics (PGNX)
Catalyst Dates: FDA Approval date of April 30th
Buy Zone: $5.00 to $5.50
Profit Zone: $6.50 or higher
Stop Zone: $4.50 or below
CorMedix (CRMD)
Catalyst Dates: Phase 3 interim analysis due out in the second quarter. Likely a buy after their earnings call in March.
Buy Zone: $.30 to $.40
Profit Zone: $.70 or higher
Stop Zone: $.25 or below
Heat Biologics (HTBX)
Catalyst Dates: Phase 2 investor meeting due on February 28th
Buy Zone: $2.50 to $2.80
Profit Zone: $3.95 or higher
Stop Zone: $2.30 or below
Sierra Oncology (SRRA)
Catalyst Dates: Phase 2 investor meeting due on February 27th
Buy Zone: $2.50 to $2.80
Profit Zone: $3.20 or higher
Stop Zone: $2.40 or below
Clearside BioMedical (CLSD)
Catalyst Dates: Phase 3 Macular edema data due in 1Q 2018. Likely in early March.
Buy Zone: $5.50 to $6.00
Profit Zone: $7.00 or higher
Stop Zone: $5.20 or below
VTV Therapeutics (VTVT)
Catalyst Dates: Phase 3 Alzheimer’s data due “early 2018” — likely March.
Buy Zone: $6.00 to $6.50
Profit Zone: $7.50 or higher
Stop Zone: $5.75 or below
EDAP Tms (EDAP)
Catalyst Dates: FDA medical device approval for prostate cancer likely late 1Q
Buy Zone: $2.40 to $2.70
Profit Zone: $3.40 or higher
Stop Zone: $2.20 or below
Arca Biosciences (ABIO)
Catalyst Dates: Phase 2b data due in March
Buy Zone: $1.60 to $1.80
Profit Zone: 2.20 or higher
Stop Zone: $1.40 or below
Flex Pharma (FLKS)
Catalyst Dates: Phase 2 Multiple Sclerosis data due out in late 1Q
Buy Zone: $4.00 to $4.400
Profit Zone: $5.00 or higher
Stop Zone: $3.50 or below
Otonomy (OTIC)
Catalyst Dates: FDA approval date of March 2, 2018.
Buy Zone: $5.50 to $5.70
Profit Zone: $6.20 or higher
Stop Zone: $5.40 or below
Nabriva Therapeutics (NBRV)
Catalyst Dates: Phase 3 antibiotic data due out “spring 2018”
Buy Zone: $5.50 to $6.00
Profit Zone: $8.00 or higher
Stop Zone: $5.20 or below
Cidara Therapeutics (CDTX)
Catalyst Dates: Phase 2 Candidemia data due in the 1Q (likely sometime in March)
Buy Zone: $6.00 to $6.50
Profit Zone: $8.40 or higher
Stop Zone: $5.75 or below
Sophiris Bio (SPHS)
Catalyst Dates: Phase 2b initial biopsy data due late First Quarter.
Buy Zone: $1.95 to $2.15
Profit Zone: $2.40 or higher
Stop Zone: $1.75 or below
